GR990100388A - Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος.... - Google Patents

Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....

Info

Publication number
GR990100388A
GR990100388A GR990100388A GR990100388A GR990100388A GR 990100388 A GR990100388 A GR 990100388A GR 990100388 A GR990100388 A GR 990100388A GR 990100388 A GR990100388 A GR 990100388A GR 990100388 A GR990100388 A GR 990100388A
Authority
GR
Greece
Prior art keywords
combination
treatment
compliance
fibrate
statin
Prior art date
Application number
GR990100388A
Other languages
Greek (el)
English (en)
Inventor
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Publication of GR990100388A publication Critical patent/GR990100388A/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR990100388A 1999-11-09 1999-11-09 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος.... GR990100388A (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR99100388 1999-11-09

Publications (1)

Publication Number Publication Date
GR990100388A true GR990100388A (el) 2001-07-31

Family

ID=10943967

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990100388A GR990100388A (el) 1999-11-09 1999-11-09 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....

Country Status (3)

Country Link
AU (1) AU1166101A (fr)
GR (1) GR990100388A (fr)
WO (1) WO2001037831A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069957A1 (fr) * 2001-03-01 2002-09-12 Grelan Pharmaceutical Co., Ltd. Composition contenant du fenofibrate
CA2456732C (fr) 2001-08-07 2012-10-30 Galephar M/F Composition pharmaceutique orale contenant une combinaison de ppar.alpha. et d'un inhibiteur de l'hmg-coa reductase
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CA2543596A1 (fr) 2003-11-07 2005-05-26 Jj Pharma, Inc. Complexes pour une therapie combinatoire stimulant les hdl
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
EP2619198A1 (fr) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés
MX2013006332A (es) * 2013-06-05 2014-12-19 Alparis Sa De Cv Composiciones farmaceuticas orales para uso en dislipidemias.
EP4445956A2 (fr) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Composé pour le traitement des affections associés à s1p1-récepteur
WO2016209809A1 (fr) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2018151873A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M.D.FEHER E.A.: "Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease", BRITISH HEART JOURNAL, vol. 74, no. 1, 1995, pages 14 - 17, XP000925445 *
M.KAYIKCIOGLU E.A.: "A new combination regimen in patients with refractory mixed hyperlipidaemia: alternate day therapy", EUROPEAN HEART JOURNAL, vol. 19, no. supp, 1998, pages 572, XP000925440 *
R.L.B.ELLEN, R.MCPHERSON: "Long-term efficacy and safety of fenofibrate and statin in the treatment of combined hyperlipidemia", AMERICAN JOURNAL OF CARDIOLOGY, vol. 81, no. 4A, 1998, pages 60B - 65B, XP000925448 *

Also Published As

Publication number Publication date
WO2001037831A1 (fr) 2001-05-31
AU1166101A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
GR990100388A (el) Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
NZ527408A (en) Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
WO2001068096A2 (fr) Polytherapie pour la prophylaxie et le traitement d'etats et de troubles hyperlipidemiques
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
JP2005532338A5 (fr)
US9642860B2 (en) Combinations of corroles and statins
US20110275649A1 (en) Combination therapy for the prevention of statin induced diabetes
HUP0105019A2 (hu) Egy koleszterinszint-csökkentő szer felhasználása
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
IL310115A (en) Treatment of sub-responders to high-dose statins
SK286260B6 (sk) Ošetrovanie migrény podávaním kyseliny alfa-lipoovej alebo jej derivátov
EP1663247B1 (fr) Utilisation d'oxcarbazepine dans l'amelioration du sommeil chez des patients souffrant de la douleur chronique
ATE400256T1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
RU2006114579A (ru) Комбинации ингибитора биосинтеза холестерина и растворимого волокна для лечения состояний, связанных с повышенным содержанием холестерина
CA2375378C (fr) Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines
US20030119892A1 (en) Methods and compositions for treating headache pain with topical NSAID compositions
Chrysant et al. Niacin‐ER/statin combination for the treatment of dyslipidemia: focus on low high‐density lipoprotein cholesterol
Mann Rosuvastatin
WO2007069033A3 (fr) Compositions pharmaceutiques
Patel et al. Chemistry of four membered heterocyclic ezetimibe as lipid lowering agent
US20190262291A1 (en) Methods and compositions for alleviating myopathy
Stein et al. Insights into statin treatment of hypertriglyceridemia
Hamilton-Craig et al. Statin-fibrate combination therapy
Ducobu et al. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study
US20080146534A1 (en) Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees